SANARA MEDTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.35 USD | +0.43% |
|
-4.26% | -21.29% |
| 04-18 | Sanara Medtech Inc. Announces $55 Million Debt Facility | CI |
| 04-05 | Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer | MT |
| Sales 2024 * | 78M 6.22B | Sales 2025 * | - | Capitalization | 279M 22.26B |
|---|---|---|---|---|---|
| Net income 2024 * | -1M -79.78M | Net income 2025 * | 4M 319M | EV / Sales 2024 * | 3.58 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-147
x | P/E ratio 2025 * |
57.8
x | Employees | 108 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sanara MedTech Inc.
More recommendations
More press releases
| 1 day | +0.43% | ||
| 1 week | -4.26% | ||
| Current month | -12.57% | ||
| 1 month | -12.57% | ||
| 3 months | -7.15% | ||
| 6 months | +20.35% | ||
| Current year | -21.29% |
1 week
31.53
33.65
1 month
31.0636.98
Current year
31.0643.25
1 year
26.0646.40
3 years
17.4150.18
5 years
2.5053.85
10 years
2.0075.00
| Managers | Title | Age | Since |
|---|---|---|---|
Zach Fleming
CEO | Chief Executive Officer | 49 | 31/10/17 |
Michael McNeil
DFI | Director of Finance/CFO | 59 | 10/04/18 |
| Chief Tech/Sci/R&D Officer | - | 31/12/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eric Tanzberger
BRD | Director/Board Member | 55 | 31/12/21 |
Roszell Mack
BRD | Director/Board Member | 57 | 31/12/21 |
Eric Major
BRD | Director/Board Member | 55 | 31/05/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 32.35 | +0.43% | 7,803 |
| 25/04/24 | 32.21 | -0.89% | 14,276 |
| 24/04/24 | 32.5 | -0.31% | 5,324 |
| 23/04/24 | 32.6 | -0.91% | 11,772 |
| 22/04/24 | 32.9 | -2.63% | 12,037 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
32.35
USD
Average target price
44
USD
Spread / Average Target
+36.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.29% | 279M | |
| +25.83% | 661B | |
| +26.09% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.58% | 231B | |
| +5.28% | 200B | |
| -8.96% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- SMTI Stock
